切换至 "中华医学电子期刊资源库"
高级检索
中华普外科手术学杂志(电子版)

中华普外科手术学杂志(电子版) ›› 2018, Vol. 12 ›› Issue (06) : 468 -471. doi: 10.3877/cma.j.issn.1674-3946.2018.06.007

所属专题： 文献；

论著

甲状腺乳头状癌组织TSHR表达与BRAFV600E基因突变的关系研究
郝少龙1, 马纪红2, 刘新承3, 陈焕杰3, 郑海涛3,†(), 宋西成4,†()   
  1. 1. 101149　首都医科大学附属北京潞河医院普外科
    2. 101149　首都医科大学附属北京潞河医院通科内科
    3. 264000　青岛大学医学院附属烟台毓璜顶医院甲状腺外科
    4. 青岛大学医学院附属烟台毓璜顶医院耳鼻喉头颈外科
  • 收稿日期:2017-06-26 出版日期:2018-12-26
  • 通信作者: 郑海涛, 宋西成

Clinical investigation of the expression of TSHR and BRAFV600E gene mutation in papillary thyroid carcinoma

Shaolong Hao1, Jihong Ma2, Xincheng Liu3, Huanjie Chen3, Haitao Zheng3,†(), Xicheng Song4,†()   

  1. 1. Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing
    2. Department of General medicine, Beijing Luhe Hospital, Capital Medical University, Beijing
    3. Department of Thyroid Surgery, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong 264000, China
    4. Department of Otorhinolaryngology-Head & Neck Surgery, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong 264000, China
  • Received:2017-06-26 Published:2018-12-26
  • Corresponding author: Haitao Zheng, Xicheng Song
  • About author:
    Corresponding author: Zheng Haitao, Email:
    Song Xicheng, Email:
  • Supported by:
    Natural Science Fundation of Shandong Province(ZR2015HL092); Key Research Project of Shandong Province(2015GSF118090); Municipal Scientific and Technological Development Project of Yantai city(2015YT06000060)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

郝少龙, 马纪红, 刘新承, 陈焕杰, 郑海涛, 宋西成. 甲状腺乳头状癌组织TSHR表达与BRAFV600E基因突变的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2018, 12(06): 468-471.

Shaolong Hao, Jihong Ma, Xincheng Liu, Huanjie Chen, Haitao Zheng, Xicheng Song. Clinical investigation of the expression of TSHR and BRAFV600E gene mutation in papillary thyroid carcinoma[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2018, 12(06): 468-471.

目的

探究甲状腺乳头癌组织中促甲状腺激素受体(TSHR)及TSHR－mRNA的表达与BRAFV600E基因突变的关系。

方法

收集甲状腺乳头状癌患者组织及正常组织标本122例，利用PCR法检测甲状腺癌组织中BRAFV600E基因突变情况，并将其分为BRAFV600E基因突变组和BRAFV600E基因野生组；应用免疫组织化学法检测甲状腺乳头状癌组织中TSHR的表达情况，并应用Western blot和RT－PCR法进行验证。应用SPSS17.0统计学软件对数据进行分析。采用χ2检验和独立样本t检验分析TSHR及TSHR－mRNA的表达与BRAFV600E基因突变的关系，P<0.05认为差异有统计学意义。

结果

TSHR及TSHR－mRNA在甲状腺乳头状癌组织中表达量明显降低(P<0.05)。BRAFV600E基因突变组的甲状腺乳头状癌组织中TSHR及TSHR－mRNA表达水平较BRAFV600E基因野生型组明显降低。

结论

甲状腺乳头状癌组织中BRAFV600E基因突变与TSHR表达下调有关。

关键词: 甲状腺肿瘤, 癌，乳头状, 受体，促甲状腺素
Objective

To explore the relationship between expression of TSHR, TSHR-mRNA and BRAFV600E gene mutation in papillary thyroid cancer.

Method

A total of 122 patients with papillary thyroid cancer were enrolled in this study. PCR was applied to detect gene mutation of BRAFV600E in papillary thyroid cancers. All the patients were divided into BRAFV600E gene mutation group and BRAFV600E gene wild-type group. Immunohistochemical assay were used to detect expression of TSHR in papillary thyroid cancers. Western blotting and Real-time quantitative PCR (RT-PCR) were used to verify the results. Statistical analysis was performed by using SPSS17.0 software. Chi-squared test and Independent sample t test were applied to analyze the relationship between the expressions of TSHR, TSHR-mRNA and BRAFV600E gene mutation. A P value <0.05 was considered as statistical significance.

Result

The expression levels of TSHR and TSHR-mRNA in papillary thyroid cancers was significant decreased (P<0.05), and the expression of TSHR and TSHR-mRNA in papillary thyroid cancers were decreased more obviously in BRAFV600E gene mutation group than those in BRAFV600E gene wild-type group.

Conclusion

BRAFV600E gene mutation is associated with the lower expression of TSHR in papillary thyroid cancers.

Key words: Thyroid Neoplasms, Carcinoma, Papillary, Receptors, Thyrotropin
表1 122例PTC组织中BRAF基因突变组和野生组TSHR表达分析(例)
基因型 阴性 弱阳性 阳性 强阳性 合计
BRAF基因突变型 2 26 36 8 72
BRAF基因野生型 1 10 24 15 50
合计 3 36 60 23 122
基因型 χ2值 df P值 95% CI
BRAF基因突变型 8.277 3 0.032 0.027～0.036
BRAF基因野生型
图1 PTC组织中TSHR同时阳性表达于细胞膜和细胞质中(HE×400)
图2 TSHR在PTC组织中的表达情况(免疫组织化学SP法，HE×400)[A.阴性表达　B．弱阳性表达　C．阳性表达　D．强阳性表达]
图3 PTC组织中TSHR的表达量Western blot试验结果　正常甲状腺对照组织(1.2.3)、BRAF基因野生型PTC组织(4.5.6)及BRAF基因突变型PTC组织(7.8.9)TSHR的表达情况。
图4 BRAF基因突变型及野生型PTC组织与正常对照甲状腺组织TSHRmRNA的相对表达量(RT－PCR)
图6 BRAFV600E基因突变型和BRAFV600E基因野生型PTC组织TSHRmRNA RT－PCR试验结果
[1]
Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer [J]．CA: a cancer journal for clinicians, 2013, 63(6): 374-394.
[2]
Davies L, welch HG. Current Thyroid cancer trends in the United States [J]. JAMA Otolaryngol Head Neck Surg, 2014, 140(4): 317-322.
[3]
Garnett MJ, Marais R. Guilty as charged: BRAF is a human oncogene [J]. Cancer Cell.2004, 6(4):313-319.
[4]
Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population [J]. J Korean Med Sci, 2013, 28(4): 534-541.
[5]
Liu X, Yan K, Lin X, et al. The association between BRAFV600E mutation and pathological features in PTC [J]. Eur Arch Otorhinolaryngol, 2014, 271(11): 3041-3052.
[6]
Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma [J]. World J Surg Oncol, 2013, 11: 99-99.
[7]
Gupta MK, Taguba L, Arciaga R, et al. Detection of circulating thyroid cancer cells by reverse transcription－PCR for thyroid－stimulating hormone receptor and thyroglobulin: The importance of primer selection. Clin Chem. 2002, 48:1862-1865.
[8]
Kinyas K, Onder S, Kosemehmetoglu K, et al. Methylation status of TSHr in well differentiated thyroid cancer by using cytologic material[J]. BMC Cancer, 2015, 15:824-824.
[9]
Khan MS, Pandith AA, Masoodi SR, et al. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status[J]. Endocrine, 2014, 47(2):449-455.
[10]
Zheng H, Wang H, Jiang H, et al. BRAF－Activated Long Non－coding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor[J]. Cancer Res Treat, 2016, 48(2):698-707.
[11]
郝少龙，马纪红，刘新承，等．外周血TSHR－mRNA检测在甲状腺乳头状癌中的临床意义[J/CD]．中华普外科手术学杂志(电子版)，2017，11(6):491-495.
[1] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[2] 麻紫月, 王贞文, 张强, 赵代伟, 张翊伦. 右侧喉不返神经1例报告[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 115-116.
[3] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[4] 田文. 甲状腺癌功能性根治颈淋巴结清扫术[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 482-482.
[5] 王宇, 徐芳泉, 周旋, 姚晓峰, 李强. 不断提高分化型甲状腺癌根治性切除规范化[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 473-476.
[6] 孙辉, 李长霖. 分化型甲状腺癌根治性切除术中的关键考量与策略[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 477-481.
[7] 高一飞, 刘根祥, 孙长华, 周广军. 喉返神经监测在无充气腋窝入路腔镜单侧甲状腺切除+中央区淋巴结清扫术中的应用效果[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 483-486.
[8] 李云龙, 夏旭良, 江志强, 刘伟, 刘凯, 唐立, 刘昊中, 张思远. 三种方法治疗分化型甲状腺癌的临床疗效[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 487-489.
[9] 韩婧, 郝少龙, 康骅. 北京市单中心甲状腺癌患者临床特征的回顾分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 490-493.
[10] 何羽. 腔镜微创手术治疗分化型甲状腺癌的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 456-458.
[11] 宋红霞, 吴玩呈. 内镜下甲状腺手术切口入路发展的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 470-472.
[12] 游涛建, 任林, 马宇. cT1-2N0期PTMC经口腔前庭入路腔镜甲状腺切除术后引流与否的可行性研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(03): 311-314.
[13] 吴波, 郑永明, 杜世强. SPECT/CT及血清sTg水平预测甲状腺癌术后131I治疗患者淋巴结转移风险的价值分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 212-216.
[14] 徐成, 王璐璐, 王少华. 洗脱液甲状腺球蛋白在甲状腺乳头状癌转移淋巴结中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2023, 17(06): 701-704.
[15] 刘通, 李菲, 朱莹, 王蓓. 剪切波弹性成像对甲状腺癌术后放射性碘治疗损伤唾液腺腺体的评估[J/OL]. 中华诊断学电子杂志, 2024, 12(02): 80-84.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号